1ST Biotherapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Seongnam Korea, Republic of (2016)

Organization Overview

First Clinical Trial
2019
NCT04165837
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

1ST Biotherapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

fb849 (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (2)

fb-101 (1 trial)

fb418 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Parkinson Disease (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4